AIinPharma News & Analysis

Eli Lilly and Insilico Partner on AI Drug Development Deal Valued at $2.75B

Eli Lilly has signed a collaboration agreement with Insilico Medicine, valued at up to $2.75 billion, to develop AI-powered drugs for the global market. This partnership extends Lilly's use of Insilico's artificial intelligence technology in drug discovery, potentially accelerating the development of innovative treatments. This deal highlights the growing integration of AI in pharmaceuticals. The financial details include milestones and deeper collaboration efforts that signal a significant commitment to advancing drug discovery methodologies.